A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Grants and Contracts Details

StatusFinished
Effective start/end date5/12/20 → 7/20/21

Funding

  • Agios Pharmaceuticals Incorporated: $38,341.00